Close Menu

NEW YORK (360Dx) – RPS Diagnostics and Atomo Diagnostics announced today that they have entered into a commercial and developmental partnership to create FebriDx, a point-of-care test that identifies clinically significant underlying febrile acute respiratory infections and aids in the differentiation between viral and bacterial infections.

FebriDx uses a fingerstick blood sample to provide clinicians with a rapid assessment of the body's immune response to acute respiratory infections. The disposable test returns results within 10 minutes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.